Table 1.
Baseline characteristics from 12 prospective studies in the pooled analysis for TFA biomarker measures and follow-up data for incident T2D
| Study | Country | Study design | Baseline year(s) of blood sampling | Incident T2D cases/total participants (n/N) | Maximum follow-up (years) | Women, n (%) | Age, years (SD) | BMI, kg/m2 (SD) | Biomarker compartment assessed |
|---|---|---|---|---|---|---|---|---|---|
| AGES-R | Iceland | PC | 2002–2006 | 28/753 | 7.8 | 451 (60) | 76 (5) | 27 (4) | PL |
| CCCC | Taiwan | PC | 1992–1995 | 302/1,443 | 10.3 | 623 (43) | 60 (10) | 23 (3) | TP |
| CHS | U.S. | PC | 1992–1993 | 291/3,007 | 22.1 | 1,804 (60) | 75 (5) | 26 (5) | PL |
| EPIC-Norfolk | U.K. | PCC | 1993–1998 | 199/383 | 12.1 | 199 (52) | 64 (8) | 26 (4) | PL, RBC |
| EPIC-Potsdam | Germany | PNC | 1994–1998 | 488/2,165 | 10.1 | 1,342 (62) | 49 (9) | 26 (4) | RBC |
| FHS | U.S. | PC | 2005–2008 | 95/1,870 | 5.8 | 1,075 (58) | 64 (8) | 28 (5) | RBC |
| HPFS | U.S. | PC | 1994 | 108/1,471 | 20.2 | 0 (0) | 65 (9) | 26 (3) | RBC, TP |
| MCCS | Australia | PNC | 1990–1994 | 333/3,711 | 9.9 | 2,057 (55.4) | 55 (9) | 27 (4) | Plasma PL |
| MESA | U.S. | PC | 2000–2002 | 297/2,234 | 11.2 | 1,214 (53.9) | 61 (10) | 28 (5) | PL |
| NHS | U.S. | PC | 1990 | 152/1,482 | 24.8 | 1,482 (100) | 60 (6) | 25 (4) | RBC, TP |
| PHS | U.S. | PCC | 1995–2001 | 60/939 | 13.9 | 0 (0) | 69 (9) | 25 (3) | RBC |
| WHIMS | U.S. | PC | 1995 | 490/5,668 | 14.1 | 6,349 (100) | 70 (4) | 28 (5) | RBC |
Characteristics reported are at the time of fatty acid biomarker measurement. AGES-R, Age, Gene/Environment Susceptibility Study (Reykjavik); CCCC, Chin-Shan Community Cardiovascular Cohort Study; CHS, Cardiovascular Health Study; EPIC-Norfolk, European Prospective Investigation into Cancer (Norfolk); EPIC-Potsdam, European Prospective Investigation into Cancer (Potsdam); FHS, Framingham Heart Study; HPFS, Health Professionals Follow-up Study; MCCS, Melbourne Collaborative Cohort Study; MESA, Multi-Ethnic Study of Atherosclerosis; NHS, Nurses' Health Study; PC, prospective cohort; PCC, prospective nested-case-control; PHS, Physician's Health Study; PNC, prospective nested case-cohort; WHIMS, Women’s Health Initiative Memory Study.